Nijal Sheth
Nephrology · Naples, FLNPI 1740422187
Payments from drug & device makers
Across 459 payments — averaging $212.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$47K
- Boehringer Ingelheim$23K
- Akebia Therapeutics Inc$21K
- AstraZeneca$782
- OPKO Pharmaceuticals, LLC$648
- Amgen$593
- plus $4K from 26 others
What the payments were for
- Speaking & faculty fees$83,81586%
- Travel & lodging$4,3624%
- Food & beverage$8,9699%
- Education$2980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 65 | $47,492 |
| Boehringer Ingelheim | 39 | $22,681 |
| Akebia Therapeutics Inc | 69 | $21,051 |
| AstraZeneca(2 entities) | 43 | $782 |
| OPKO Pharmaceuticals, LLC | 28 | $648 |
| Amgen(2 entities) | 29 | $593 |
| Mallinckrodt Hospital Products Inc. | 24 | $554 |
| Otsuka America Pharmaceutical, Inc. | 23 | $513 |
| Calliditas Therapeutics US Inc. | 19 | $481 |
| Travere Therapeutics, Inc. | 18 | $403 |
| Vifor Pharma, Inc. | 17 | $344 |
| Novo Nordisk | 15 | $327 |
| Bayer | 12 | $255 |
| Novartis | 11 | $231 |
| Aurinia Pharma U.S., Inc. | 11 | $229 |
| Johnson & Johnson | 1 | $106 |
| Fresenius USA Marketing, Inc. | 5 | $83 |
| GSK | 6 | $80 |
| Ardelyx, Inc. | 3 | $78 |
| Daiichi Sankyo Inc. | 4 | $76 |
| Vantive US Healthcare LLC | 2 | $76 |
| Scpharmaceuticals Inc. | 3 | $76 |
| Nxstage Medical, Inc. | 1 | $63 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $34 |
| Apellis Pharmaceuticals, Inc. | 1 | $28 |
| Mallinckrodt Enterprises LLC | 1 | $28 |
| Cormedix Inc. | 1 | $27 |
| Coala Life Inc | 3 | $26 |
| Mannkind Corporation | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$97,444 in reported general payments places this provider in the 85th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 333 | $390,333 |
| JardianceEmpagliflozin | 282 | $369,866 |
| JynarqueTolvaptan | 14 | $233,325 |
| TarpeyoBudesonide | 12 | $198,280 |
| FilspariSparsentan | 16 | $193,124 |
| VelphoroSucroferric Oxyhydroxide | 38 | $143,664 |
| KerendiaFinerenone | 93 | $123,511 |
| VeltassaPatiromer Calcium Sorbitex | 60 | $97,363 |
| RayaldeeCalcifediol | 56 | $74,589 |
| LokelmaSodium Zirconium Cyclosilicate | 31 | $35,089 |
| EntrestoSacubitril/Valsartan | 17 | $22,175 |
| OzempicSemaglutide | 17 | $18,157 |
| DapagliflozinDapagliflozin Propanediol | 20 | $12,852 |
| Sevelamer Carbonate | 46 | $11,342 |
| Calcitriol | 338 | $7,298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $782 | $425,423364 claims |
| Boehringer IngelheimJardiance | $22,681 | $369,866282 claims |
| Otsuka America Pharmaceutical, Inc.Jynarque | $513 | $233,32514 claims |
| Calliditas Therapeutics US Inc.Tarpeyo | $481 | $198,28012 claims |
| Travere Therapeutics, Inc.Filspari | $403 | $193,12416 claims |
| Fresenius USA Marketing, Inc.Velphoro | $83 | $143,66438 claims |
| BayerKerendia | $255 | $123,51193 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $648 | $74,58956 claims |
| NovartisEntresto | $231 | $22,17517 claims |
| Novo NordiskOzempic | $327 | $18,15717 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $21 | $93246 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 756 nephrology providers in Florida.
Other nephrology in Naples
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
- Edouard MartinLauderdale Lakes$2.7M
- Jorge PosadaCoral Gables$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.